|
|
| Bringing a new therapeutic to market is a complex, time-consuming journey, but the right CDMO partnership can change everything. That’s why Outsourced Pharma serves to connect you with ideal collaborators to accelerate your project needs. To help you achieve your goals, we’re excited to announce that the Outsourced Pharma Capacity Update (OPCU) has evolved into the Outsourced Pharma Capabilities Update — a refreshed name that better reflects the value we deliver. While capacity insights remain core to our mission, this rebrand highlights our expanded focus on capabilities, expertise, and innovation across the CDMO landscape. Looking ahead, our PARTNER WEEK continues to grow, with plans for an extended program and sessions organized by capability area throughout 2026. This structure will make it easier than ever to identify the right partner, no matter where you are in the development or manufacturing process. Join us for the next Outsourced Pharma Capabilities Update on January 27, 2026, and discover the partners, insights, and expertise that can bring your therapeutic vision to life. Fill Finish Capabilities Update | January 27. 2026 at 11:00 AM EST
Viral Vectors Capabilities Update | January 27, 2026 at 1:00 PM EST |
|
|
Ropack Pharma Solutions | For clinical trials, we provide full support from warehousing to returns. Join Chris Vounasis, Head of Commercial, for a webinar on our technologies and 2025–2026 capacity. | Request Information | Ropack Pharma Solutions |
|
|
Alcami | Partner with a flexible, high-quality manufacturing expert to accelerate your bench-to-clinic journey, strengthen your supply chain, and ensure seamless commercialization of OSD therapies. | Request Information | Alcami |
|
|
Douglas CDMO | Choose an experienced CDMO specializing in high-potency softgels and liquids to ensure high-quality products, responsive service, and reliable solutions across complex therapeutic areas. | Request Information | Douglas CDMO |
|
|
Pfizer CentreOne | With specialized tech like laser drilling, multilayer coating, and orally disintegrating tablets, our state-of-the-art facilities provide the infrastructure to support your most demanding OSD requirements. | Request Information | Pfizer CentreOne Oral Solids |
|
|
Lonza | Get an overview of our AI-assisted early phase toolkit, which combines predictive modeling, formulation screening, and data-driven insights to accelerate molecule progression. | Request Information | Lonza |
|
|
|
Alcami | Whether you're preparing for IND, scaling commercial operations, or navigating complex regulatory pathways, gain actionable strategies and updates to help you move forward with confidence. | Request Information | Alcami |
|
|
SGS | We provide a range of solutions, including method development, validation, and transfer; PK and PD bioanalysis; ELISA and multiplex assays; bioassays; and immunogenicity testing. | Request Information | SGS |
|
|
Mabion | This end-to-end solution covers every development stage, from early clone selection and small-scale manufacturing to process scale-up, large-scale production, and quality control. | Request Information | Mabion |
|
|
KBI Biopharma | Leveraging decades of expertise, analytical capabilities, and regulatory knowledge, we deliver phase-appropriate solutions that streamline development, reduce risk, and accelerate timelines. | Request Information | KBI Biopharma |
|
|
Abzena | Explore ThioBridge™ as an efficient site-specific conjugation technology to generate ADCs and other conjugate modalities, such as oligoconjugates and conjugates. | Request Information | Abzena |
|
|
MilliporeSigma | MilliporeSigma and Simtra’s collaboration streamlines every stage — from bioconjugation and linker/payload supply to formulation development and final fill/finish. | Request Information | MilliporeSigma |
|
|
Simtra BioPharma Solutions | Our collaboration with MilliporeSigma encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish. | Request Information | Simtra BioPharma Solutions |
|
|
